GRIN2C: A Potential Drug Target for Neurotransmission and Cellular Processes

Target Name: GRIN2C

NCBI ID: G2905

GRIN2C

GRIN2C: A Potential Drug Target for Neurotransmission and Cellular Processes

G protein-coupled receptors (GRPs) are a family of transmembrane proteins that play a crucial role in cellular signaling. They are involved in various physiological processes, including sensory perception, neurotransmission, and hormone signaling. The N-methyl-D-aspartate (NMDA) receptor subtype 2C (GRIN2C) is a well-established GRP that is expressed in various tissues and plays a significant role in neurotransmission. In this article, we will discuss the biology and potential drug targets of GRIN2C.

History of GRIN2C

GRIN2C was first identified in 2002 as a highly homophilic receptor that was expressed in the rat brain and was sensitive to agonists that blocked its function. It is a member of the GRIN family of receptors, which includes GRIN1C, GRIN2A, GRIN3A, and GRIN4A. These receptors are known to play a role in neurotransmission and are involved in various signaling pathways.

Function of GRIN2C

GRIN2C is a nuclear-resident receptor that is primarily expressed in the cerebral cortical cortical regions. It is involved in neurotransmission and in the regulation of various cellular processes, including cell survival, migration, and synaptic plasticity.

GRIN2C is activated by agonists that are specific for its N-terminus. This receptor is also known to be sensitive to inhibitors that can inhibit its function.GRIN2C is a G protein-coupled receptor, which means that it is involved in intracellular signaling through the interaction with G protein-coupled receptors.

Drug Targets for GRIN2C

Due to its unique structure and its involvement in various cellular processes, GRIN2C has been identified as a potential drug target. Several studies have shown that inhibitors of GRIN2C have been shown to be effective in treating various neurological and psychiatric disorders, including depression, anxiety, and schizophrenia.

One of the potential drug targets for GRIN2C is the neurotransmitter glutamate, which is known to play a crucial role in neurotransmission. Studies have shown that inhibitors of GLUT4, which is a known agonist for GRIN2C, have been shown to be effective in treating anxiety and depression.

Another potential drug target for GRIN2C is the protein brain-derived neurotrophic factor (BDNF), which is involved in the regulation of neuron survival and differentiation. Studies have shown that inhibitors of BDNF have been shown to be effective in treating depression and anxiety.

GRIN2C is also known to be involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. This process is important for the formation and maintenance of neural connections, which are critical for learning and memory.

In conclusion, GRIN2C is a well-established GRP that is involved in neurotransmission and various cellular processes. Its unique structure and its involvement in various signaling pathways make it a potential drug target. Further research is needed to fully understand the biology of GRIN2C and to develop effective treatments for its associated disorders.

Protein Name: Glutamate Ionotropic Receptor NMDA Type Subunit 2C

Functions: Component of NMDA receptor complexes that function as heterotetrameric, ligand-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Channel activation requires binding of the neurotransmitter glutamate to the epsilon subunit, glycine binding to the zeta subunit, plus membrane depolarization to eliminate channel inhibition by Mg(2+) (PubMed:26875626). Sensitivity to glutamate and channel kinetics depend on the subunit composition (Probable). Plays a role in regulating the balance between excitatory and inhibitory activity of pyramidal neurons in the prefrontal cortex. Contributes to the slow phase of excitatory postsynaptic current, long-term synaptic potentiation, and learning (By similarity)

The "GRIN2C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GRIN2C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets